Oral mucositis (OM) is the inflammation of oral mucosa and is manifested by pain and erythema or ulcerations. This condition is generally seen as a complication due to side effects of chemotherapy and radiotherapy in cancer patients. The systemic effects of cytotoxic chemotherapy agents and radiation effects on oral mucosa led to oral mucositis. The National Institutes of Health estimates that more than 400,000 patients in the U.S. are diagnosed with oral mucositis annually. Since the prevalence of cancer patients is on rise across the globe, the market for OM therapeutics is also expanding. In addition, the pain emanated from oral mucositis and the resultant need to cure the condition at the earliest is the foremost driver for the growth of this market.
Use For sample: Thinking about report: Please observe the beneath the hyperlinks to satisfy your necessities; Request for the Report sample: http://www.persistencemarketresearch.com/samples/5585
The oral mucositis therapeutics market includes several kinds of drug formulations and treatments such as cryotherapy, growth factors, antioxidants, anti-inflammatory agents, low-level laser therapy (LLLT), mouthwashes, barriers and coating agents. On the basis of geography, the global oral mucositis therapeutics market is segmented into four major regions, namely, North America, Europe, Asia-Pacific and Rest of the World. North America is the largest market for OM therapeutics, closely followed by the European region.
The currently marketed major preparations for oral mucositis are Gelclair, Caphosol and Kepivance. Recently, the FDA granted "Fast Track" Designation for SGX942 (Soligenix, Inc.) for the treatment of oral mucositis in patients with head and neck cancer. This drug along with MuGard (tasteless viscous mouth rinse) and pipeline candidate drug nepidermin (Daewoong Pharmaceutical Co.) are expected to further drive the oral mucositis therapeutics market. The major restraint for the development of this market is that most of the drugs are not to be ingested and therefore restricts their usage for esophageal ulcers.
Use For to: Request TOC (desk of content material), Figures and Tables of the report: http://www.persistencemarketresearch.com/toc/5585
Some of the key players in the global oral mucositis therapeutics market include Access Pharmaceuticals, Inc., EKR Therapeutics, Inc., EUSA Pharma Inc., Swedish Orphan Biovitrum Ltd., Soligenix, Inc., Daewoong Pharmaceutical Co., Eisai Inc., and BioAlliance Pharma SA.
Key geographies evaluated in this report are:
- North America
- France, Germany, Italy, Spain, and the UK
- Eastern Europe
- Latin America
Key features of this report
- Drivers, restraints, and challenges shaping the Oral Mucositis Therapeutics market dynamics
- Latest innovations and key events in the industry
- Analysis of business strategies of the top players
- Oral Mucositis Therapeutics market estimates and forecasts(2015 -2021)
Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.
To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.
Persistence Market Research
7th Floor, New York City,
NY 10007, United States,
USA - Canada Toll Free: 800-961-0353